This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Rebamipide

Otsuka Holdings Co., Ltd.

Drug Names(s): OPC-12759E, OPC759, Mucosta (Japan)

Description: OPC759 enhances tear secretion and increase the levels of mucin covering the conjunctiva and cornea of the eye.

Deal Structure: Otsuka and Novartis
On February 7, 2005, Novartis announced that it had in-licensed Rebamipide from Otsuka Pharmaceutical Company. Under the agreement, Novartis will obtain an exclusive license with the right to sub-license the compound globally, excluding Japan and selected Asian countries. Novartis will pay an upfront fee and annual royalties.

In 2007, Novartis ended its agreement with Otsuka and returned the rights to sub-licence Rebamipide back to Otsuka.

Otsuka and Acucela
In September 2008, Otsuka Pharmaceutical and Acucela announced that the companies entered into an agreement to co-develop Rebamipide. Under the agreement, the parties will collaborate in the clinical development efforts forRebamipide in the United States, with Acucela spearheading the regulatory strategy to gainapproval for the product in the United States. Upon regulatory approval of Rebamipide, theparties may negotiate the terms under which Acucela may co-promote Rebamipide with...See full deal structure in Biomedtracker


Rebamipide News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug